Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1 dose-finding trial of cabozantinib (cabo) and trifluridine/tipiracil (FDT/TPI) in metastatic colorectal carcinoma (mCRC).
Authors
Farshid Dayyani
University of California Irvine, Division of Hematology/Oncology, Department of Medicine, Orange, CA;
Farshid Dayyani , Jasmine Balangue , Jennifer Brooke Valerin , Jason A. Zell , Thomas H Taylor , May Thet Cho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04868773
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 98)
DOI
10.1200/JCO.2023.41.4_suppl.98
Abstract #
98
Poster Bd #
E15
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors.
First Author: Li-Yuan Bai
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update.
First Author: Chao Yin
Poster
2019 ASCO Annual Meeting
A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).
First Author: Stefan Kasper
Poster
2019 Gastrointestinal Cancers Symposium
Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.
First Author: Yoshito Komatsu